Geoff Meacham
Stock Analyst at Citigroup
(4.32)
# 362
Out of 5,182 analysts
306
Total ratings
58.95%
Success rate
13.18%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPRX Royalty Pharma | Maintains: Buy | $50 → $66 | $50.20 | +31.47% | 5 | May 7, 2026 | |
| MRK Merck & Co. | Reinstates: Neutral | $125 | $112.30 | +11.31% | 13 | May 6, 2026 | |
| BIIB Biogen | Maintains: Neutral | $190 → $200 | $191.38 | +4.50% | 21 | May 1, 2026 | |
| PFE Pfizer | Maintains: Neutral | $26 → $27 | $26.48 | +1.96% | 8 | Apr 29, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $50 → $60 | $56.95 | +5.36% | 5 | Apr 29, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $156 → $165 | $134.06 | +23.08% | 10 | Apr 13, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Buy | $14 → $16 | $9.67 | +65.46% | 2 | Mar 27, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $95 → $125 | $81.81 | +52.79% | 3 | Mar 24, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $115 → $125 | $98.85 | +26.45% | 5 | Mar 19, 2026 | |
| BNTX BioNTech SE | Maintains: Buy | $145 → $130 | $93.02 | +39.75% | 3 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $97 → $85 | $54.12 | +57.06% | 4 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $575 → $585 | $425.00 | +37.65% | 7 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $58 | $46.45 | +24.87% | 2 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $120 | $84.63 | +41.79% | 8 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $107.85 | -21.19% | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $15.20 | +25.00% | 6 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $64 | $56.25 | +13.78% | 9 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $315 → $345 | $329.09 | +4.83% | 14 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $235 → $230 | $202.71 | +13.46% | 22 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $16.09 | +210.75% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $49 | $14.54 | +237.00% | 3 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $8 | $2.48 | +222.58% | 6 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $75 | $64.49 | +16.30% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $700 | $709.10 | -1.28% | 24 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $72 | $12.96 | +455.56% | 8 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $28 | $48.54 | -42.32% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $34.85 | +43.47% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $93 | $52.42 | +77.41% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $14 | $9.27 | +51.02% | 3 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $54 | $67.45 | -19.94% | 6 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $6 | $9.23 | -34.99% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $1 | $1.94 | -48.45% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $112 → $4 | $1.24 | +222.58% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $974.96 | +12.83% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $120 → $20 | $19.89 | +0.55% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $32.75 | -5.34% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $222.51 | -23.60% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $0.93 | +1,718.38% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $1.37 | +1,651.82% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $14.64 | -72.67% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $10.35 | +170.66% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.31 | +1,371.86% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $3.14 | +1,014.65% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.44 | +2,816.67% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $7.26 | +23.97% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $10.42 | +475.82% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $26.58 | -13.47% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $97.77 | -16.13% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $569.18 | -83.31% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $19.98 | +300.40% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $149.59 | -9.75% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $10.53 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $4.17 | +379.62% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $9.74 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $295.91 | -46.61% | 5 | Nov 8, 2017 |
Royalty Pharma
May 7, 2026
Maintains: Buy
Price Target: $50 → $66
Current: $50.20
Upside: +31.47%
Merck & Co.
May 6, 2026
Reinstates: Neutral
Price Target: $125
Current: $112.30
Upside: +11.31%
Biogen
May 1, 2026
Maintains: Neutral
Price Target: $190 → $200
Current: $191.38
Upside: +4.50%
Pfizer
Apr 29, 2026
Maintains: Neutral
Price Target: $26 → $27
Current: $26.48
Upside: +1.96%
Kiniksa Pharmaceuticals International,
Apr 29, 2026
Maintains: Buy
Price Target: $50 → $60
Current: $56.95
Upside: +5.36%
Gilead Sciences
Apr 13, 2026
Maintains: Buy
Price Target: $156 → $165
Current: $134.06
Upside: +23.08%
MeiraGTx Holdings
Mar 27, 2026
Maintains: Buy
Price Target: $14 → $16
Current: $9.67
Upside: +65.46%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $95 → $125
Current: $81.81
Upside: +52.79%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Buy
Price Target: $115 → $125
Current: $98.85
Upside: +26.45%
BioNTech SE
Mar 11, 2026
Maintains: Buy
Price Target: $145 → $130
Current: $93.02
Upside: +39.75%
Mar 11, 2026
Maintains: Buy
Price Target: $97 → $85
Current: $54.12
Upside: +57.06%
Mar 10, 2026
Maintains: Buy
Price Target: $575 → $585
Current: $425.00
Upside: +37.65%
Mar 4, 2026
Maintains: Buy
Price Target: $55 → $58
Current: $46.45
Upside: +24.87%
Mar 2, 2026
Maintains: Buy
Price Target: $110 → $120
Current: $84.63
Upside: +41.79%
Mar 2, 2026
Initiates: Buy
Price Target: $85
Current: $107.85
Upside: -21.19%
Feb 20, 2026
Maintains: Buy
Price Target: $15 → $19
Current: $15.20
Upside: +25.00%
Feb 6, 2026
Maintains: Neutral
Price Target: $60 → $64
Current: $56.25
Upside: +13.78%
Feb 4, 2026
Maintains: Neutral
Price Target: $315 → $345
Current: $329.09
Upside: +4.83%
Jan 27, 2026
Maintains: Neutral
Price Target: $235 → $230
Current: $202.71
Upside: +13.46%
Jan 9, 2026
Initiates: Buy
Price Target: $50
Current: $16.09
Upside: +210.75%
Dec 2, 2025
Maintains: Buy
Price Target: $58 → $49
Current: $14.54
Upside: +237.00%
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.48
Upside: +222.58%
Nov 5, 2025
Maintains: Neutral
Price Target: $50 → $75
Current: $64.49
Upside: +16.30%
Oct 29, 2025
Maintains: Buy
Price Target: $660 → $700
Current: $709.10
Upside: -1.28%
Oct 27, 2025
Downgrades: Neutral
Price Target: $75 → $72
Current: $12.96
Upside: +455.56%
Oct 23, 2025
Maintains: Neutral
Price Target: $30 → $28
Current: $48.54
Upside: -42.32%
Oct 17, 2025
Maintains: Buy
Price Target: $42 → $50
Current: $34.85
Upside: +43.47%
Oct 17, 2025
Maintains: Buy
Price Target: $78 → $93
Current: $52.42
Upside: +77.41%
Aug 27, 2025
Upgrades: Buy
Price Target: $12 → $14
Current: $9.27
Upside: +51.02%
Jun 25, 2025
Maintains: Buy
Price Target: $50 → $54
Current: $67.45
Upside: -19.94%
Jun 17, 2025
Initiates: Sell
Price Target: $6
Current: $9.23
Upside: -34.99%
Apr 2, 2025
Downgrades: Underperform
Price Target: $7 → $1
Current: $1.94
Upside: -48.45%
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $1.24
Upside: +222.58%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $974.96
Upside: +12.83%
Oct 30, 2024
Downgrades: Underperform
Price Target: $120 → $20
Current: $19.89
Upside: +0.55%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $32.75
Upside: -5.34%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $222.51
Upside: -23.60%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $0.93
Upside: +1,718.38%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $1.37
Upside: +1,651.82%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $14.64
Upside: -72.67%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $10.35
Upside: +170.66%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $2.31
Upside: +1,371.86%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $3.14
Upside: +1,014.65%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.44
Upside: +2,816.67%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $7.26
Upside: +23.97%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $10.42
Upside: +475.82%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $26.58
Upside: -13.47%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $97.77
Upside: -16.13%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $569.18
Upside: -83.31%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $19.98
Upside: +300.40%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $149.59
Upside: -9.75%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $10.53
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $4.17
Upside: +379.62%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.74
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $295.91
Upside: -46.61%